Review of the cardiovascular safety of dipeptidyl peptidase-4 inhibitors and the clinical relevance of the CAROLINA trial

Marile Santamarina* and Curt J. Carlson

Abstract

Background: Cardiovascular (CV) disease (CVD) is a well-recognized complication of type 2 diabetes mellitus (T2DM) and there is a clinical need for glucose-lowering therapies that do not further increase CV risk in this population. Although sulfonylureas (SUs) may be used as second-line therapy for patients requiring additional therapy after first-line metformin to improve glycemic control, their long-term effects on CV outcomes remain uncertain, and a wide range of alternative agents exist including dipeptidyl peptidase-4 (DPP-4) inhibitors.

Methods: Literature searches in PubMed (2013–2018) were conducted with terms for DPP-4 inhibitors combined with CV terms, with preference given to cardiovascular outcomes trials (CVOTs). Reference lists from retrieved articles and diabetes guidelines were also considered.

Results: This narrative review discusses current evidence for the CV safety of these agents, describes the long-term CV effects of DPP-4 inhibitors, including effects on CV events, mortality, the risk for heart failure hospitalization, and highlights the need for further research into the CV effects of SU therapy. Although SUs remain a treatment option for T2DM, the long-term effects of these agents on CV outcomes are unclear, and further long-term studies are required. For DPP-4 inhibitors, uncertainties have been raised about their long-term effect on hospitalization for heart failure in light of the results of SAVOR-TIMI 53, although the findings of other DPP-4 inhibitor CVOTs in T2DM and data analyses have suggested these agents do not increase the occurrence of adverse CV outcomes.

Conclusions: Based on recent CVOTs and guideline updates, the choice of add-on to metformin therapy for patients with T2DM and established CV disease should be a sodium-glucose co-transporter-2 inhibitor or a glucagon-like peptide-1 agonist with proven CV benefit. Additional treatment options for those individuals who require therapy intensification, as well as in patients with T2DM and without established CVD include DPP-4 inhibitors and SUs. Since few head-to-head trials have compared the effects of different oral glucose-lowering agents on CV outcomes in T2DM, with most CVOTs using placebo as a comparator, the CAROLINA trial will provide important information on the comparative CV safety of a commonly prescribed SU and a DPP-4 inhibitor.

Keywords: Type 2 diabetes mellitus, Cardiovascular diseases, DPP-4 inhibitors, Linagliptin, Sulfonylureas
Background
Cardiovascular (CV) disease (CVD) is a well-recognized complication of type 2 diabetes mellitus (T2DM), and is the leading cause of mortality and morbidity for patients with T2DM [1, 2]. In view of the risk of CVD in patients with T2DM and the need for long-term treatment, the choice of glucose-lowering therapy should prioritize agents that have recently been proven to reduce CV risk for patients with T2DM and established atherosclerotic CVD (ASCVD) or chronic kidney disease (CKD). For patients without established ASCVD or CKD, the choice of glucose-lowering therapy should take account of individual patient characteristics (e.g., hypoglycemia risk, effects on body weight), as well as cost and CV neutrality [1, 3].

The influence of many glucose-lowering agents on long-term CV risk was unclear until the recent availability of results from randomized placebo-controlled cardiovascular outcomes trials (CVOTs), which were recommended by the US Food and Drug Administration (FDA) over 10 years ago in response to CV safety concerns for glucose-lowering drugs [4]. Several CVOTs with published results have shown a neutral effect on ASCVD for dipeptidyl peptidase-4 (DPP-4) inhibitors compared with placebo when added to standard care for patients with T2DM and high CV risk or established CVD [5–8]. Moreover, the CAROLINA (CARDiovascular Outcome Study of LINAglipitin versus Glimepiride in Patients with Type 2 Diabetes; NCT01243424) trial has randomized 6041 patients with relatively early T2DM and increased CV risk or with established CV complications to receive once-daily therapy with either linagliptin 5 mg or glimepiride 1–4 mg, in addition to standard care, and will assess the effect of each treatment on CV events [9, 10]. CAROLINA is the largest head-to-head comparison of an SU and a DPP-4 inhibitor, and will provide important additional evidence on the comparative long-term CV safety of these agents in T2DM.

CV outcomes have also been evaluated with other classes of glucose-lowering drugs, and important results have been reported for sodium-glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists. The Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes trial (EMPA-REG OUTCOME) [11], demonstrated lower rates of the composite 3-point major cardiovascular event (MACE) outcome of CV death, non-fatal myocardial infarction (MI), or non-fatal stroke (14% relative risk reduction); death from CV causes (38% relative risk reduction); death from any cause (32% relative risk reduction); and hospitalization for heart failure (35% relative risk reduction), with the SGLT2 inhibitor empagliflozin compared with placebo, when added to standard care [11]. The CANagliflozin cardioVascular Assessment Study (CANVAS) Program showed a reduction in the primary composite 3-point MACE outcome (hazard ratio [HR] 0.86; 95% confidence interval [CI] 0.75–0.97; P < 0.001 for non-inferiority; P = 0.02 for superiority); however, no statistically significant difference in CV mortality was observed (HR 0.87; 95% CI 0.72–1.06) [12]. The Dapagliflozin Effect on Cardiovascular Events–Thrombolysis in Myocardial Infarction 58 (DECLARE–TIMI 58) trial is the most recent and largest CVOT for the SGLT2 inhibitor class (N > 17,000). In this trial, dapagliflozin was associated with a lower rate of CV death or hospitalization for heart failure versus placebo (HR 0.83; 95% CI 0.73–0.95; P = 0.005) [13], primarily due to a 27% reduction in heart failure hospitalizations. Dapagliflozin treatment showed no effect on CV mortality and dapagliflozin was non-inferior, but not statistically superior compared with placebo, for 3-point MACE (HR 0.93; 95% CI 0.84–1.03; P = 0.17). Among the GLP-1 receptor agonist CVOTs, the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial showed a decreased risk of the 3-point MACE for liraglutide compared with placebo (HR 0.87; 95% CI 0.78–0.97; P < 0.001 for non-inferiority; P = 0.01 for superiority) [14]. Also, a non-inferiority study with semaglutide showed that among patients with T2DM and high CV risk, the occurrence of 3-point MACE was lower among patients receiving semaglutide versus placebo, when added to standard care [15].

In response to the findings of recent CVOTs, treatment recommendations for T2DM have been updated. Current consensus statements from the American Diabetes Association (ADA) [3], the ADA and the European Association for the Study of Diabetes (EASD) [16], and the American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE) [17] recommend metformin as first-line therapy in the treatment of individuals with T2DM. For patients with T2DM and ASCVD, the latest guidelines from the ADA and ADA/EASD recommend addition of an SGLT2 inhibitor or a GLP-1 receptor agonist with proven CV benefit [1, 16]. For patients with ASCVD and a high risk of heart failure or coexisting heart failure, SGLT2 inhibitors might be appropriate [1]. In individuals with T2DM without established ASCVD or CKD, the choice of second-line therapy is based on minimizing risks, especially hypoglycemia and weight gain, cost, and patient preference. If subsequent third-line glucose-lowering therapies are required, similar principles apply. Several treatment options are available, including DPP-4 inhibitors [3, 17], and sulfonylureas (SUs); the latter remain an option when cost is a major consideration [3]. SUs were the first available oral glucose-lowering drugs, and have been in clinical use since the late 1950s [18, 19]. The low cost and familiarity of SUs in clinical practice are possible factors underlying their continued use in T2DM [18, 20].
The aim of this review is to provide a summary of current evidence for the long-term CV safety of DPP-4 inhibitors and the role of further research into the long-term CV effects of these agents. We also consider the available CV safety data for SUs, and the importance of the CAROLINA trial as the largest head-to-head study to evaluate the relative safety of a DPP-4 inhibitor and an SU.

Methods
The Medline database was searched via PubMed to retrieve relevant articles on DPP-4 inhibitors between 2013 and 2018 (limits: English language, humans). The search results were combined with CV-related terms, and cardiovascular outcome trial-related terms (e.g., TECOS, SAVOR). Other relevant literature was obtained based on personal knowledge and experience, including evidence from cardiovascular outcomes trials, meta-analyses, and systematic literature reviews. A narrative overview of the literature was then synthesized based on manual assessment of the retrieved literature.

Results
Published evidence from clinical trials with SUs or DPP-4 inhibitors
There is uncertainty surrounding the overall CV safety of SUs in the treatment of T2DM. Since the publication of a study by the University Group Diabetes Program in 1970, concerns have been raised about the long-term CV safety of SUs after an increased occurrence of CV mortality was observed among SU-treated patients versus patients managed with diet alone or diet plus insulin [21]. The tolbutamide arm of the study was stopped early due to the increased number of CV deaths versus placebo that were observed at an interim analysis of data during the study. In response to this finding, the FDA included a warning in the prescribing information of all US-marketed SUs about the 2.5-fold increased risk of CV mortality associated with SU therapy in this study [22, 23].

More recent evidence has also suggested a link between SU therapy and an increased risk of CV events and mortality [24], although controversy remains [10, 25, 26]. In two large trials of long-term treatment of T2DM, in which SUs were widely used in the intensive glucose-lowering arms, no increased CV risk was reported [27, 28]. The UK Prospective Diabetes Study (UKPDS) reported that after 10 years of intensive glucose-lowering therapy, no adverse effects on CV outcomes were observed with the three agents (two first-generation SUs, chlorpropamide and glibenclamide, or insulin) [28]. Similarly, the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) study showed no significant differences in the rate of death from CV causes, over a median follow-up of 5 years, among patients who received intensive glucose control (involving modified-release gliclazide with target glycated hemoglobin [HbA1c] of ≤6.5%) versus standard glycemic control (HbA1c target based on local guidelines) [27]. In addition, the long-term, randomized Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents. Intervention Trial (TOSCA.IT) showed that the incidence of CV events was similar with SUs (mostly glibenpiride and gliclazide) and pioglitazone, when added to existing metformin therapy, over a median follow-up period of 57.3 months [29]. However, in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study, intensive glucose control was associated with an increase in all-cause mortality and CV mortality compared with standard therapy (SUs were used in more than half of patients in both groups) over a mean follow-up period of 3.5 years [24]. In addition, the findings of several retrospective cohort studies using the ACCORD data have suggested an increased risk of adverse CV outcomes associated with SU therapy compared with metformin [30–32]. A retrospective cohort study of patients with T2DM newly treated with SUs versus metformin showed an increased risk of all-cause and CV mortality among patients newly treated with SU monotherapy compared with metformin, with respective adjusted relative risks of 1.43 (95% CI 1.15–1.77) and 1.70 (95% CI 1.18–2.45) [32]. Another retrospective cohort study showed significantly higher risks of all-cause mortality (HR 1.46; 95% CI 1.21–1.76) and major adverse CV events (HR 1.58; 95% CI 1.19–2.10) for SU monotherapy compared with metformin plus SU combination therapy [31]. A further study indicated a higher risk of mortality (of which around one-fourth of deaths were due to an acute ischemic event) with first-generation SUs (adjusted HR 2.1; 95% CI 1.0–4.7 for patients receiving doses higher than the median) and second-generation SUs (glyburide, adjusted HR 1.3; 95% CI 1.2–1.4 for higher doses), with a relationship between greater daily dose and increased risk of mortality [30]. Evidence from other observational studies has indicated either an increased risk of CV events and/or mortality associated with SU therapy [33, 34] or no increased risk [35–37]. However, this evidence is largely based on retrospective analysis and it remains unclear whether SU use directly contributes to an increased risk of CV events [26], and whether this is more likely to occur with first- versus second-generation SUs [10, 38]. A recent review of CV outcomes reported in meta-analyses of randomized controlled trials and observational studies involving SUs suggested that overall the risk of CV events and mortality is higher in patients with T2DM treated with SUs versus other types of glucose-lowering agents (including DPP-4 inhibitors) or placebo, albeit given that such analyses have limitations [39] (Table 1).

SUs are also generally regarded as having the highest risk of hypoglycemia of any non-insulin therapy [17, 40].
The elevated incidence of hypoglycemia with SU therapy is related to its mode of action, which involves stimulation of insulin release from pancreatic beta cells that occurs independently of plasma glucose levels [41]. Hypoglycemia is recognized as an important clinical complication with these agents [3, 17], and the overall cost of SU therapy could be underestimated if the health care financial burden of treatment of hypoglycemic events are not taken into account [42, 43]. Patients receiving SUs are more likely than those treated with newer agents, such as DPP-4 inhibitors, to experience severe hypoglycemic episodes requiring hospital treatment, adding substantial health care costs to the care of patients with T2DM [43]. The occurrence of hypoglycemic events is a particular risk for elderly patients [44], for whom the additional risks of falls and fractures are also a concern, adding to the clinical and economic burden of hypoglycemia.

Another important consequence of severe hypoglycemia is an approximately 2-fold increased risk of CV events and mortality [45–47] that can also lead to an elevated incidence of hospital admission and related health care costs [48, 49]. The association of severe hypoglycemia and CV events is not entirely explained by the presence of comorbid illness [45], and several possible mechanisms have been suggested to underlie this observation. Hypoglycemia has been described as a pro-arrhythmic, pro-inflammatory and pro-thrombotic state that could lead to vascular changes associated with CVD [50, 51]. Furthermore, prolongation of the QT interval has been demonstrated during episodes of hypoglycemia, increasing the risk of arrhythmia and sudden death at low blood glucose levels [52, 53]. A link between hypoglycemia and the occurrence of myocardial ischemia has also been demonstrated, particularly in patients who experience substantial fluctuations in blood glucose levels [54]. It has also been suggested that hypoglycemic episodes can lead to impaired autonomic function, which contributes to increased mortality in patients with T2DM and CVD [55].
avoidance of hypoglycemia, therefore, may be an important component of reducing the risk of adverse CV events and mortality in patients with T2DM [45]. It remains unclear whether a high frequency of severe hypoglycemic events is a marker of poor health in patients with existing high CV risk or whether the hypoglycemia itself is a causal factor for adverse CV events [46, 50, 56–58]. The findings of recent clinical trials have added to the controversy surrounding hypoglycemia and CV events. In TOSCA.IT, second-line treatment with SUs (glimepiride [48%], gliclazide [50%] or glibenclamide [2%]) was compared with pioglitazone over a median of 4.8 years (57.3 months). A similar incidence of CV events was observed in both groups, despite frequent occurrence of hypoglycemic events in the SU group [29]. Further uncertainty about the relationship between severe hypoglycemia and CV events was raised in a post hoc analysis of data from the Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS), in which participants with T2DM and CVD were randomized to receive sitagliptin or placebo in addition to standard-of-care therapy [5] (almost half of patients in both groups were receiving background SU therapy) [59]. Although DPP-4 inhibitor therapy was not associated with an increase in the occurrence of hypoglycemic events, the analysis demonstrated a greater risk of major CV events following episodes of severe hypoglycemia, and also almost twice the risk of severe hypoglycemic episodes among patients who experienced a previous major CV event [59]. The authors suggest these findings indicate that severe hypoglycemia could be a marker of patient frailty rather than a cause of increased CV events or CV mortality.

Independent of the effects of hypoglycemia, a suggested mechanism for the potential adverse CV effects of SU therapy relates to their potential to block ion channels within the myocardium including the KATP channel [60]. Blockade of KATP channels is thought to underlie the mode of action of SUs in pancreatic beta cells, however it is unclear whether blockade of these channels in the myocardium leads to detrimental effects in patients with T2DM at risk for CVD [60]. SU-induced impairment of the vasodilatory response to myocardial ischemia has been postulated [61]. Furthermore, it is possible that findings with older, first-generation SUs do not apply to newer agents [60]. There is evidence to suggest that unlike other SUs, glimepiride does not impair the myocardial protection induced by ischemic preconditioning, an effect in which brief periods of myocardial ischemia, non-lethal to cardiac myocytes, decreases injury to cardiac muscle during subsequent longer term ischemia [62]. This apparent benefit over the other SUs indicates that comparison of glimepiride with other second-line treatments for T2DM would be of great interest and relevant to current clinical practice [63, 64]. In the absence of convincing evidence of a causal association between SU use and an increased risk of CV events or mortality, further research is clearly required, and there remains a clinical need for approaches to glycemic control that do not further increase CV risk [65].

CV safety of DPP-4 inhibitors

CVOTs involving DPP-4 inhibitors were conducted in a manner to allow the patients’ physicians to adjust their diabetes therapies as needed to maintain glycemic targets generally in accordance with national or regional guidelines, although the exact definition of standard care varied. The Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus – Thrombolysis in Myocardial Infarction 53 (SAVOR-TIMI 53) [7], Examination of Cardiovascular Outcomes With Alogliptin Versus Standard of Care (EXAMINE) [8] and TECOS [5] trials demonstrated that the addition of saxagliptin, alogliptin and sitagliptin, respectively, had a neutral effect (i.e., did not increase or decrease the event rate versus placebo) on the primary composite endpoint (defined as CV death, non-fatal stroke or non-fatal MI) in SAVOR-TIMI 53 and EXAMINE, and as CV death, stroke, MI or hospitalization for unstable angina in TECOS) in patients with high baseline risk for CV events (Table 1). SAVOR-TIMI 53 [7] demonstrated that the addition of saxagliptin to existing therapy had a neutral effect on individual components of the primary composite endpoint (namely the risk of CV death, non-fatal MI or non-fatal ischemic stroke) versus placebo; however, saxagliptin treatment was associated with a significantly increased risk of heart failure-related hospital admissions. After concerns raised by the findings of SAVOR-TIMI 53 [7], several studies have investigated the effect of DPP-4 inhibitors on the risk of heart failure in patients with T2DM. The EXAMINE trial [8] showed that the addition of alogliptin to standard care in patients with T2DM and a history of recent acute coronary syndrome was not associated with an increase in major CV events versus placebo, although a post hoc analysis showed a non-significant 19% increased risk of hospitalization for heart failure among alogliptin- versus placebo-treated patients [66]. In TECOS, no increases in major adverse CV events or hospitalization for heart failure were observed for sitagliptin versus placebo [5]. Subsequently, a retrospective observational study that analyzed data from a US insurance claims database (Truven Health MarketScan Commercial and Medicare Supplemental databases) found no association between hospitalization for heart failure and treatment with a DPP-4 inhibitor relative to SU therapy, or treatment with saxagliptin relative to sitagliptin [67]. Although the causal mechanism for the increased risk of heart failure observed with DPP-4 inhibitor therapy in SAVOR-TIMI 53 and EXAMINE is currently unknown, sympathetic nervous system activation resulting in cardiomyocyte injury and death has been proposed as a possible explanation, as the actions of stromal derived
factor-1, neuropeptide Y, and substance P to stimulate β-adrenergic receptors and cause cardiomyocyte apoptosis may be potentiated by DPP-4 inhibition [68].

More recently, the Cardiovascular and Renal Microvascular Outcome Study with Linagliptin in Patients with Type 2 Diabetes Mellitus (CARMELINA) trial has demonstrated the CV and renal safety of linagliptin versus placebo when added to standard care in patients with T2DM who were at high risk of vascular complications [6]. Participants were generally at high vascular risk at baseline, with long-standing T2DM (mean duration, 14.7 years) and established CKD, with or without CVD [69]. Compared with placebo, the addition of linagliptin to standard care over a median of 2.2 years did not increase the risk of the composite CV outcome of 3-point MACE (CV death, non-fatal MI, non-fatal stroke) (HR 1.02; 95% CI 0.89–1.17). There was also no increase in risk of the kidney composite outcome of renal death, end-stage kidney disease, or sustained ≥40% decrease in eGFR from baseline (HR 1.04; 95% CI 0.89–1.22). Importantly, linagliptin did not increase the risk of hospitalization for heart failure (HR 0.90; 95% CI 0.74–1.08). This study provides new information on the safety of linagliptin administration in a population at high cardio-renal risk who generally have limited treatment options, and have been under-represented in previous CVOTs in patients with T2DM [6, 69].

The data from the DPP-4 inhibitor CVOTs contrasted with the results of pooled analyses and meta-analyses of smaller trials that had suggested a reduction in the risk of major CV events was associated with DPP-4 inhibitor treatment [70]. For example, a meta-analysis of 36 placebo-controlled randomized clinical trials of DPP-4 inhibitors reported no significant differences in all-cause mortality (relative risk reduction 1.03; 95% CI 0.95–1.12) and CV mortality (relative risk reduction 1.02; 95% CI 0.92–1.12) with the use of these agents [71]. Similar results were reported in other meta-analyses of DPP-4 inhibitor studies [72, 73]. Whereas an earlier meta-analysis of 70 randomized clinical trials involving DPP-4 inhibitors stated that treatment with DPP-4 inhibitors reduced the risk of CV events, as the Mantel-Haenzel odds ratio for MACE (defined here as CV death, non-fatal MI, stroke, acute coronary syndromes, and/or heart failure reported as serious adverse events) was 0.71 (95% CI 0.59–0.86) [74]. However, these results are not surprising given that these trials were designed to assess metabolic rather than CV endpoints, most had durations below 2 years, management of concurrent medications varied, and they utilized a heterogeneous study population of T2DM patients with a generally low risk of CV events [39]. The differences in CV outcomes between the CVOTs and meta-analyses of “non-CVOTs” for DPP-4 inhibitors may be largely explained by these differences in study and patient characteristics [70].

DPP-4 inhibitor selection: Focus on linagliptin
Linagliptin, a DPP-4 inhibitor with an established role in the management of T2DM, has a unique pharmacology within its drug class. One distinctive characteristic of linagliptin is that its route of elimination is via the bile and gut, unlike the other currently available DPP-4 inhibitors that undergo mainly renal excretion [75, 76]. Thus, no dosage adjustment is required for linagliptin in patients with CKD, whereas sitagliptin, saxagliptin, and alogliptin may be used in renal impairment with dosage adjustment [3]. In contrast to other CVOTs in the DPP-4 inhibitor class, the CARMELINA trial included a substantial proportion of patients with T2DM; 74% had prevalent kidney disease [6]. As discussed above, linagliptin was non-inferior in the primary 3-point MACE outcome when compared with placebo in patients with T2DM and established CVD or CKD on top of standard-of-care treatment [6]. The CV safety of linagliptin was previously evaluated in three pooled analyses of data from the clinical trial program. A pooled analysis of 19 randomized, controlled trials showed that the incidence of prospectively adjudicated CV events was similar for linagliptin versus pooled active comparators or placebo [77]. Randomized clinical trials have demonstrated that linagliptin, both alone and when used in combination with other glucose-lowering agents, is effective and well tolerated, with a low incidence of hypoglycemia [78–81]. Also, a post hoc pooled analysis of four randomized clinical trials of linagliptin added on to insulin therapy for T2DM demonstrated a neutral effect of linagliptin on the occurrence of major CV events [82]. A further pooled analysis of safety data from 19 trials evaluated a high-risk patient population with T2DM and pre-existing coronary artery disease and showed that the addition of linagliptin to existing treatment was not associated with an increase in cardiac adverse events [83]. A 2-year study of linagliptin versus glimepiride added to metformin therapy in patients with inadequately controlled T2DM showed significantly fewer CV events among linagliptin-treated patients compared with those receiving glimepiride (12 vs 26 patients; relative risk 0.46; 95% CI 0.23–0.91) [84]. However, this study was neither powered nor designed to evaluate the effect of linagliptin or glimepiride on CV events, and the low number of CV events reported in this study preclude drawing any definitive conclusions.

Further information on the comparative CV safety of linagliptin versus the SU, glimepiride, will be provided with the results of the CAROLINA trial. Baseline demographic data from CAROLINA show that patients had a diagnosis of T2DM for a median of 6.2 years (with
40.6% ≤ 5 years) at entry into the study. This is a shorter duration than in the other DPP-4 inhibitor CVOTs (T2DM duration: median 10.3 years in SAVOR-TIMI 53; median 7.1 years in EXAMINE; mean 11.6 years in TECOS and mean 14.7 years in CARMELINA). It remains to be seen whether intervention at an earlier stage in the disease will have an important impact on CV and other outcomes in the long term.

Discussion
Clinical implications of the CAROLINA trial
The management of T2DM presents unique challenges largely due to the progressive nature of the condition, the frequent presence or development of comorbidities, and the need for the use of additional agents over time that incorporate the individual needs of the patient. At present, treatment choices are based on consideration of a range of factors including efficacy, low risk of hypoglycemia, effect on body weight, and overall safety data. More recently, the importance of the reduction of CV risk has been emphasized [1, 17] in light of the findings of CVOTs that have shown CV risk reduction with SGLT2 inhibitors [11, 12, 85] and GLP-1 receptor agonists [14, 15], and the latest ADA recommendations state that second-line therapy for patients with established CVD should include an agent proven to reduce major adverse CV events and CV mortality (currently SGLT2 inhibitors or GLP-1 agonists) [1]. These agents also have been shown to reduce the risk of secondary outcomes such as heart failure and progression of renal disease, and therefore treatment guidelines now recommend that the presence of ASCVD, heart failure and CKD be taken into account when making treatment choices [1]. To further assist with the selection of appropriate treatments for individuals with T2DM, there is a need for head-to-head clinical trials to evaluate the CV safety and efficacy of glucose-lowering agents in long-term clinical use.

Although SUs remain a treatment option for T2DM [3, 17], the long-term effects of these agents on CV outcomes are uncertain. Furthermore, there is some evidence to suggest that the therapeutic durability of SUs is unreliable, with a decline in efficacy of these agents (in terms of fasting plasma glucose and HbA1c levels) demonstrated over long-term follow-up [29, 86, 87]. SUs consistently demonstrate a progressive decline in glycemic control after the initial 18 months of treatment [88, 89], with data from the UKPDS indicating that glycemic control with SU monotherapy becomes inadequate (fasting plasma glucose > 15.0 mmol/L or development of hyperglycemic symptoms) in 44% of patients after 5 years of treatment [90]. A well-recognized problem with SU therapy is the risk of hypoglycemic events [3, 17]. As stated previously, the prognostic clinical implications of severe hypoglycemia associated with SU therapy is currently unclear, although it appears that its occurrence might be an indicator of deteriorating health and could indicate the need for increased monitoring of affected patients. Further research will help shed light on the question of whether a causal link exists between severe hypoglycemia and increased CV events and mortality. This has important clinical implications for the selection of T2DM treatments; if indeed the occurrence of hypoglycemia is a marker of patient vulnerability to CV events, the selection of agents on the basis of hypoglycemia risk alone might not result in an accompanying reduction in the risk of CV events or mortality.

The DPP-4 inhibitors are newer agents among the recommended options for second-line therapy in T2DM [3, 17]. Although uncertainties were raised about the long-term effect of DPP-4 inhibitors on hospitalization for heart failure following publication of the results of SAVOR-TIMI 53 [7], the findings of other DPP-4 inhibitor CVOTs in T2DM [5, 8], including the recently published CARMELINA trial [6], in addition to retrospective evaluation [67] and pooled analyses [77, 82, 83] of these agents, have provided some reassurance. To date, no head-to-head trials have compared the effects of different oral glucose-lowering agents on CV outcomes in patients with T2DM [1, 91]. The CAROLINA trial will provide an important opportunity to evaluate the comparative CV safety of a commonly prescribed SU and a DPP-4 inhibitor and, thus, CAROLINA will be the first CVOT to provide a head-to-head comparison of a DPP-4 inhibitor with another class of oral glucose-lowering agent.

Conclusions
Recent evidence and guideline updates indicate that the choice of add-on to metformin therapy should be based on consideration of agents with proven CV risk reduction (currently SGLT2 inhibitors or GLP-1 agonists). When additional glucose-lowering is required, DPP-4 inhibitors and SUs may be considered, and the results of the CAROLINA trial will provide evidence on the comparative long-term CV safety of these agents.

Abbreviations
ACE: American Association of Clinical Endocrinologists; ACCORD: Action to Control Cardiovascular Risk in Diabetes; ADA: American College of Endocrinology; ADA: American Diabetes Association; ADVANCE: Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation; ASCVD: Atherosclerotic cardiovascular disease; CAROLINA: Cardiovascular and Renal Microvascular Outcome Study with Linagliptin in Patients with Type 2 Diabetes Mellitus; CAROLINA: Cardiovascular Outcome Study of Linagliptin versus Glimepiride in Patients with Type 2 Diabetes; CI: Confidence interval; CKD: Chronic kidney disease; CV: Cardiovascular; CVD: Cardiovascular disease; CVOT: Cardiovascular outcomes trial; DECLARE–TIMI 58: Dapagliflozin Effect on Cardiovascular Events–Thrombolysis in Myocardial Infarction 58; DPP-4: Dipeptidyl peptidase-4; EASD: European Association for the Study of Diabetes; EMPA-REG Outcome: Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes; EXAMINE: Examination of Cardiovascular Outcomes With Albiglutin Versus Standard of Care; FDA: US Food and Drug Administration; GLP-1: Glucagon-like peptide-1; HbA1c: Glycated hemoglobin; HR: Hazard
ratio; LEADER: Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results; MACE: Major adverse cardiovascular event; MI: Myocardial infarction; SAVOR-TIMI 53: Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus – Thrombolysis in Myocardial Infarction 53; SGLT2: Sodium-glucose co-transporter-2; SU: Sulfonylurea; T2DM: Type 2 diabetes mellitus; TEOS2: Trial Evaluating Cardiovascular Outcomes with Sitagliptin; TOCADET: Thiiazolidinediones Or Sulphonylureas and Cardiovascular Accidents.Intervention Trial; UGDP: University Group Diabetes Program; UKPDS: UK Prospective Diabetes Study

Acknowledgments

The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors, and were fully responsible for all content and editorial decisions, were involved at all stages of manuscript development, and approved the final version that reflects the authors’ interpretations and conclusions. Writing support was provided by Jennifer Garrett, MB BS and Debra Brocksmith, MB ChB, PhD, of Envision Scientific Solutions, which was contracted and compensated by BIPI for this service.

Funding

This article was supported by Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI). The authors received no direct compensation related to the development of the manuscript.

Availability of data and materials

Not applicable.

Authors’ contributions

MS and CC contributed to writing and critically revising the manuscript and approved the final draft submitted for publication.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interest

The competing interests of the authors declare they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 1 October 2018 Accepted: 27 February 2019 Published online: 15 March 2019

References

1. American Diabetes Association. 10. Cardiovascular Disease and Risk Management. Standards of Medical Care in Diabetes-2019. Diabetes Care. 2019;42:S103–23.
2. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ. 2006;332:73–8.
3. American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2019. Diabetes Care. 2019;42:S100–S102.
4. Guidance for Industry: Diabetes mellitus – evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf. Accessed 12 Mar 2019.
5. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Kom S, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:252–42.
6. Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, Alexander JH, Pencina M, Toto RD, Warner C, et al. Effect of Liraglutide vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMEDINA randomized clinical trial. JAMA. 2019;321:69–79.
7. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EE, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317–26.
8. White WB, Cannon CP, Heller SR, Nissen SE, Bergeman RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327–35.
9. Marx N, Rosenstock J, Kahn SE, Zinman B, Kastelein JJ, Lachin JM, Espeland MA, Bluhmki E, Matthews M, Ryckaert B, et al. Design and baseline characteristics of the CardiOHL and Glimperide in type 2 diabetes (CAROLINA*). Diab Vasc Dis Res. 2015;12:164–74.
10. Rosenstock J, Marx N, Kahn SE, Zinman B, Kastelein JJ, Lachin JM, Bluhmki E, Patel S, Johansen OE, Woeber HJ. Cardiovascular outcome trials in type 2 diabetes and the sulfonylurea controversy: rationale for the active-comparator CAROLINA trial. Diab Vasc Dis Res. 2015;10:289–301.
11. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Matthews M, Devins T, Johansen OE, Woeber HJ, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28.
12. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fuchs G, Ernodu N, Shaw W, Law G, Desai M, Matthews DR, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–57.
13. Wiviott SD, Raz I, Bonaca MP, Mosinzzon Q, Kato ET, Cahn A, Silverman MG, Bansilal S, Bhatt DL, Leiter LA, et al. The design and rationale for the Dapagliflozin effect on cardiovascular events (DECLARE-TIMI 58) trial. Am Heart J. 2018;200:83–9.
14. Marso SP, Daniels GH, Brown-Forand S, Kristensen P, Malm J, Nauck MA, Nissen SE, Pocock S, Pouliot NR, Ravn LS, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–22.
15. Marso SP, Bain SC, Consoli A, Blaschewicz FG, Jodar E, Leiter LA, Linyay L, Rosenstock J, Seufert J, Warren ML, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–44.
16. Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ, Buse JB. Management of Hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41:2669–701.
17. Garber AJ, Abrahamson MJ, Barzilay JI, Blinde L, Bloomgarden ZT, Busch MA, Dagogo-Jack S, Defronzo RA, Einhorn D, Fonseca VA, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of endocrinology on the comprehensive type 2 diabetes management algorithm – 2018 executive summary. Endocr Pract. 2018;24:120–30.
18. Code of Federal Regulations Title 21, Volume 5. Sec. 310.517 Labeling for oral antihypoglycemic drugs. Accessed 12 Mar 2019.
19. History of the sulphonylureas. 13 June 2016; Diapedia 8104336183 rev. no. 18. https://doi.org/10.14466/da.8104336183.18
20. Hampi C, Borders-Hemphill V, Moceny DG, Wysowski DK. Use of antidiabetic drugs in the U.S., 2003–2012. Diabetes Care. 2014;37:1367–74.
21. Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of the effects of hyperglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes. 1970;19(Suppl):789–830.
22. American Diabetes Association. Labeling of oral antihypoglycemic drugs. Diabetes. 1972;21:833.
23. Brown-Forand S, Kristensen P, Malm J, Nauck MA, Nissen SE, Pocock S, Pouliot NR, Ravn LS, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–22.
24. Hampi C, Borders-Hemphill V, Moceny DG, Wysowski DK. Use of antidiabetic drugs in the U.S., 2003–2012. Diabetes Care. 2014;37:1367–74.
25. Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of the effects of hyperglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes. 1970;19(Suppl):789–830.
26. American Diabetes Association. Labeling of oral antihypoglycemic drugs. Diabetes. 1972;21:833.
27. Code of Federal Regulations Title 21, Volume 5. Sec. 310.517 Labeling for oral hypoglycemic drugs of the sulfonylurea class. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfr/CFRSearch.cfm?fct=310.517. Accessed 12 Mar 2019.
28. ACCORD Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, BJT, Buse JB, Cushman WC, Gennuth S, Ismail-Beigi F, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–2559.
29. Engler RL, Yellon DM. Sulfonylureas KATP blockade in type II diabetes and preconditioning in cardiovascular disease: time for reconsideration. Circulation. 1996;94:2297–301.
30. Shimoda M, Kaku K. Controversy about the relationship between sulfonylurea use and cardiovascular events and mortality. J Diabetes Investig. 2016;7:674–6.
31. Advance Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Mare M, Cooper M, Glazou P, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72.
32. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:87–53.
29. Vaccaro O, Masulli M, Nicolucci A, Bonora E, Del Prato S, Maggioni AP, Rivellese AA, Squartini S, Giora CB, Sesti G, et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylurea in patients with type 2 diabetes inadequately controlled with metformin (TOSCA-II): a randomised, multicentre trial. Lancet Diabetes Endocrinol. 2017;5:887–97.

30. Simpson SH, Majumdar SR, Tsuyuki RT, Ericht DT, Johnson JA. Dose-response relation between sulfonylureas drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ. 2006;174:169–74.

31. Morgan CL, Poole CD, Evans M, Barnett AH, Jenkins-Jones S, Currie CJ. What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes. J Clin Endocrinol Metab. 2012;97:4065–12.

32. Evans JM, Ogston SA, Emms-Smith A, Morris AD. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia. 2006;49:930–6.

33. Johnson JA, Majumdar SR, Simpson SH, Toth EL. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care. 2002;25:2244–8.

34. Rao AD, Kuhadaya N, Reynolds K, Fonseca VA. Is the combination of antidiabetic drugs added to metformin therapy on glycemic control, weight and cardiovascular risk. JAMA Intern Med. 2014;174:251–9.

35. Morgan CL, Poole CD, Evans M, Barnett AH, Jenkins-Jones S, Currie CJ. What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes. J Clin Endocrinol Metab. 2012;97:4065–12.

36. Landstedt-Hallin L, Englund A, Adamson U, Lins PE. Increased QT dispersion during hypoglycaemia in patients with type 2 diabetes mellitus. J Intern Med. 1999;246:299–307.

37. Cha SA, Yun JS, Lim TS, Kang YG, Lee KM, Song KH, Yoo KD, Park YM, Ko SH, Ahn YB. Baseline-corrected QT (QTC) interval is associated with prolongation of QTc during severe hypoglycaemia in patients with type 2 diabetes mellitus. Diabetes Metab. 2016;40:463–72.

38. Desouza C, Salazar H, Cheong B, Murgio J, Fonseca V. Association of hypoglycaemia and cardiac ischemia: a study based on continuous monitoring. Diabetes Care. 2003;26:2126–30.

39. Adler GK, Bonyhay I, Failing H, Waring E, Dotson S, Freeman R. Antecedent hypoglycaemia impairs autonomic cardiovascular function: implications for rigorous glycemic control. Diabetes. 2005;58:360–6.

40. Adler GK, Bonyhay I, Failing H, Waring E, Dotson S, Freeman R. Antecedent hypoglycaemia impairs autonomic cardiovascular function: implications for rigorous glycemic control. Diabetes. 2005;58:360–6.

41. Adler GK, Bonyhay I, Failing H, Waring E, Dotson S, Freeman R. Antecedent hypoglycaemia impairs autonomic cardiovascular function: implications for rigorous glycemic control. Diabetes. 2005;58:360–6.

42. Adler GK, Bonyhay I, Failing H, Waring E, Dotson S, Freeman R. Antecedent hypoglycaemia impairs autonomic cardiovascular function: implications for rigorous glycemic control. Diabetes. 2005;58:360–6.
placebo-controlled clinical trial in patients with type 2 diabetes and high
heart-related risk. Cardiovasc Diabetol. 2018;17:39.
70. Mannucci E, Mosenzon O, Avogaro A. Analyses of results from
cardiovascular safety trials with DPP-4 inhibitors: cardiovascular outcomes,
 predefined safety outcomes, and pooled analysis and meta-analysis. Diabetes Care. 2016;39(Suppl 2):S196–204.
71. Rehman MB, Tudrej BV, Soustree J, Buissou M, Archambault P, Pouchain D,
 Vaillant-Roussel H, Guyeffer F, Fallie JL, Peraudit-Pochat MC, et al. Efficacy
 and safety of DPP-4 inhibitors in patients with type 2 diabetes: meta-
analysis of placebo-controlled randomized clinical trials. Diabetes Metab.
2017;43:48–58.
72. Savarese G, D’Amore C, Federici M, De Martino F, Dellegrottaglie S,
 Marciano C, Ferrazzano F, Losco T, Lund LH, Trinarco B, et al. Effects of
dipeptidyl peptidase 4 inhibitors and sodium-glucose linked coTransporter
2 inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis. Int J Cardiol. 2016;220:595–601.
73. Xu S, Zhang X, Tang L, Zhang F, Tong N. Cardiovascular effects of dipeptidyl
peptidase-4 inhibitor in diabetic patients with and without established
cardiovascular disease: a meta-analysis and systematic review. Postgrad
Med. 2017;129:205–15.
74. Monami M, Ahren B, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4
inhibitors and cardiovascular risk: a meta-analysis of randomized clinical
trials. Diabetes Obes Metab. 2013;15:112–20.
75. Deacon CF, Holst JJ. Linagliptin, a xanthine-based dipeptidyl peptidase-4
inhibitor with an unusual profile for the treatment of type 2 diabetes.
Expert Opin Investig Drugs. 2010;19:133–40.
76. Blech S, Ludwig-Schwellinger E, Grafé-Mody EU, Wuthof B, Wagner K. The
metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor,
linagliptin, in humans. Drug Metab Dispos. 2010;38:667–78.
77. Rosenstock J, Marx N, Neubacher D, Seck T, Patel S, Woerle HJ, Johansen
OE. Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive
patient-level pooled analysis of prospectively adjudicated cardiovascular
events. Cardiovasc Diabetol. 2015;14:57.
78. Del Prato S, Barnert AH, Huisman H, Neubacher D, Woerle HJ, Dugi KA.
Effect of linagliptin monotherapy on glycaemic control and markers of
beta-cell function in patients with inadequately controlled type 2 diabetes:
a randomized controlled trial. Diabetes Obes Metab. 2011;13:258–67.
79. Inagaki N, Watada H, Murali M, Kagimura T, Gong Y, Patel S, Woerle HJ.
Linagliptin provides effective, well-tolerated add-on therapy to pre-existing
oral antidiabetic therapy over 1 year in Japanese patients with type 2
diabetes. Diabetes Obes Metab. 2013;15:833–43.
80. Owens DR, Swallow R, Dugi KA, Woerle HJ. Efficacy and safety of linagliptin
in persons with type 2 diabetes inadequately controlled by a combination
of metformin and sulphonylurea: a 24-week randomized study. Diabet Med.
2011;28:1352–61.
81. Taskinen MR, Rosenstock J, Tamminen I, Kubik R, Patel S, Dugi KA, Woerle
HJ. Safety and efficacy of linagliptin as add-on therapy to metformin in
patients with type 2 diabetes: a randomized, double-blind, placebo-
controlled study. Diabetes Obes Metab. 2011;13:65–74.
82. Zinnman B, Ahren B, Neubacher D, Patel S, Woerle HJ, Johansen OE. Efficacy
and cardiovascular safety of linagliptin as an add-on to insulin in type 2
diabetes: a pooled comprehensive post hoc analysis. Can J Diabetes. 2016;
40:50–7.
83. Lehcke M, Leiter LA, Huhnke U, Thiemann S, Bhandari A, Meinicke T,
Johansen OE. Safety and efficacy of linagliptin in patients with type 2
diabetes mellitus and coronary artery disease: analysis of pooled events
from 19 clinical trials. J Diabetes Complicat. 2016;30:1378–84.
84. Gallwitz B, Rosenstock J, Rauch T, Bhattacharya S, Patel S, von Eynatten M,
Dugi KA. Woerle HJ. 2-year efficacy and safety of linagliptin compared with
glimepiride in patients with type 2 diabetes inadequately controlled on
metformin: a randomised, double-blind, non-inferiority trial. Lancet. 2012;
380:475–83.
85. Wilkott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MC,
Zelniker TA, Kuder JF, Murphy SA, et al. Dapagliflozin and cardiovascular
outcomes in type 2 diabetes. N Engl J Med. 2018.
86. UK Prospective Diabetes Study Group. UK prospective diabetes study 16:
overview of 6 years’ therapy of type II diabetes: a progressive disease.
Diabetes. 1995;44:1249–58.
87. Holman RR. Long-term efficacy of sulfonylurea: a United Kingdom
prospective diabetes study perspective. Metabolism. 2006;55(Suppl 1):S2–5.
88. DeFronzo RA, Eldor R, Abdul-Ghani M. Pathophysiologic approach to
therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care.
2013;36(Suppl 2):S127–38.
89. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz
BG, Lachin JM, O’Neill MC, Zinman B, et al. Glycemic durability of
rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;
355:2427–37.
90. Matthews DR, Cull CA, Stratton IM, Holman RR, Turner RC. UKPDS 26:
Sulphonylurea failure in non-insulin-dependent diabetic patients over six
years. UK prospective diabetes study (UKPDS) group. Diabet Med. 1998;15:
297–303.
91. Bennett WL, Maruthur NM, Singh S, Segal JB, Wilson LM, Chatterjee R,
Marinopoulos SS, Puhar MA, Ranasinghe P, Block L, et al. Comparative
effectiveness and safety of medications for type 2 diabetes: an update
including new drugs and 2-drug combinations. Ann Intern Med. 2011;154:
602–13.
92. Varvaki Rados D, Catani Pinto L, Reck Remonti L, Bauermann Leitao C, Gross
JL. The association between sulfonylurea use and all-cause and
cardiovascular mortality: a meta-analysis with trial sequential analysis of
randomized clinical trials. PLoS Med. 2016;13:e1001992.
93. Monami M, Genovese S, Mannucci E. Cardiovascular safety of sulfonylureas:
a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2013;15:
938–53.
94. Phung OJ, Schwartzman E, Allen RW, Engel SS, Rajpathak SN.
Sulphonylureas and risk of cardiovascular disease: systematic review and
meta-analysis. Diabet Med. 2013;30:1160–71.